Telomir Pharmaceuticals , Inc. (NASDAQ: TELO) announced positive preclinical data for its lead candidate, Telomir-1, in human progeria cell lines. The tests demonstrated significant cellular ...

MIAMI - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a $55 million market cap biotechnology company currently trading near its 52-week low of $1.85, reported Wednesday that its lead drug candidate ...

Telomir Pharmaceuticals, a preclinical stage pharmaceutical company, has reported promising results from its latest preclinical studies on Telomir-1, its lead candidate for treating Hutchinson-Gilford ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and ...

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years.